Enovis CORP.
- ENOV · NYSE
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Lewisville, TX
- 7,802 employees
- CIK 0001420800
Updated from SEC filings through
Top things to know
Executives
-
Damien McDonald Chief Executive Officer 4, 2026-09-04 - Phillip Benjamin (Ben) Berry SVP, Chief Financial Officer 4, 2026-05-14
- Phillip B. Berry Senior Vice President and Chief Financial Officer 10-K, 2026-02-26
-
Oliver Engert Chief Administrative Officer 4, 2026-09-08 - Laura Lee Singleton SVP, Chief HR Officer 3, 2026-04-10
-
Bradley J. Tandy SVP and Chief Legal Officer 4, 2026-03-10
What leadership is saying
“Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Enovis CORP is a U.S. public company in orthopedic, prosthetic & surgical appliances & supplies (SIC 3842), headquartered in Lewisville, TX. It trades as ENOV on NYSE. Revenue was $2.2B in the fiscal year ending December 31, 2025, +6.7% from the year before. It reported about 7,802 employees. Damien McDonald is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.2B 10-K, 2026-02-26 | $2.1B 10-K, 2026-02-26 | $1.7B 10-K, 2026-02-26 | $1.6B 10-K, 2025-02-26 | $1.4B 10-K, 2024-02-22 |
| Operating income | -$1.1B 10-K, 2026-02-26 | -$776M 10-K, 2026-02-26 | -$65.7M 10-K, 2026-02-26 | -$71.2M 10-K, 2025-02-26 | -$62.8M 10-K, 2024-02-22 |
| SG&A | $1.1B 10-K, 2026-02-26 | $1.0B 10-K, 2026-02-26 | $830M 10-K, 2026-02-26 | $773M 10-K, 2025-02-26 | $666M 10-K, 2024-02-22 |
| Net income | -$1.2B 10-K, 2026-02-26 | -$825M 10-K, 2026-02-26 | -$33.3M 10-K, 2026-02-26 | -$13.3M 10-K, 2025-02-26 | $71.7M 10-K, 2024-02-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Damien McDonald | Chief Executive Officer | 4, 2026-09-04 |
| Matthew L. Trerotola | Named in proxy bio: Executive Advisor, former Chief Executive Officer | DEF 14A, 2026-04-06 |
| Phillip Benjamin (Ben) Berry | SVP, Chief Financial Officer | 4, 2026-05-14 |
| Phillip “Ben” Berry | Named in proxy bio: Chief Financial Officer | DEF 14A, 2026-04-06 |
| Phillip B. Berry | Senior Vice President and Chief Financial Officer | 10-K, 2026-02-26 |
| Oliver Engert | Chief Administrative Officer | 4, 2026-09-08 |
| Laura Lee Singleton | SVP, Chief HR Officer | 3, 2026-04-10 |
| Terry Ross Group President, Prevention & Recovery at Enovis | Named in proxy bio: Group President, P&R | DEF 14A, 2026-04-06 |
| Bradley J. Tandy | SVP and Chief Legal Officer | 4, 2026-03-10 |
| Patricia A. Lang | SVP, Chief HR Officer | 4, 2026-03-10 |
| Louis Vogt | GROUP PRESIDENT, RECON | 4, 2026-03-10 |
| Terry D. Ross | GROUP PRESIDENT, P&R | 4, 2026-03-10 |
| Patricia Lang | Senior Vice President and Chief Human Resources Officer | 10-K, 2026-02-26 |
| John Kleckner | Principal Accounting Officer | 4, 2026-03-10 |
| Barbara W. Bodem | Board member (per proxy) bio: Director | DEF 14A, 2026-04-06 |
| Philip A. Okala | Board member (per proxy) bio: Director | DEF 14A, 2026-04-06 |
What Enovis CORP does
Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 57.7 million (as of October 30, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $1.9B (as of July 4, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 2 (period ending October 2, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting April 6, 2026 (filed April 6, 2026) | DEF 14A, April 6, 2026 |
| Auditor | Ernst & Young LLP (Philadelphia, Pennsylvania) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 4, 2026 | Oliver Engert Chief Administrative Officer | Buy | 2,660 | $50K | Form 4, September 8, 2026 |
| September 4, 2026 | Damien McDonald Chief Executive Officer | Buy | 13,035 | $250K | Form 4, September 4, 2026 |
| September 3, 2026 | Oliver Engert Chief Administrative Officer | Buy | 7,598 | $150K | Form 4, September 4, 2026 |
| June 15, 2026 | Oliver Engert Chief Administrative Officer | Buy | 1,000 | $21K | Form 4, June 16, 2026 |
| June 11, 2026 | Oliver Engert Chief Administrative Officer | Buy | 1,200 | $26K | Form 4, June 15, 2026 |
| June 10, 2026 | Oliver Engert Chief Administrative Officer | Buy | 1,000 | $23K | Form 4, June 11, 2026 |
| June 1, 2026 | Oliver Engert Chief Administrative Officer | Buy | 1,000 | $22K | Form 4, June 3, 2026 |
| March 13, 2026 | Oliver Engert Chief Administrative Officer | Buy | 1,000 | $24K | Form 4, March 16, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-01
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-19
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-12-15
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-12-10
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2025-11-14
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Enovis CORP
- What does Enovis CORP do?
- In its own words, from Item 1 of its 10-K: "Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy."
- What is Enovis CORP's revenue?
- $2.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Enovis CORP profitable?
- Enovis CORP reported net income of -$1.2B for the fiscal year ending December 31, 2025.
- How many employees does Enovis CORP have?
- About 7,802 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Enovis CORP?
- Damien McDonald, Chief Executive Officer, as named in a 4 filed September 4, 2026.
- Who is the CFO of Enovis CORP?
- Phillip Benjamin (Ben) Berry, SVP, Chief Financial Officer, as named in a 4 filed May 14, 2026.
- Where is Enovis CORP headquartered?
- Lewisville, TX.
- What is Enovis CORP's stock ticker?
- ENOV on NYSE.
- What industry is Enovis CORP in?
- Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC code 3842.
- What is Enovis CORP's website?
- enovis.com.
- When does Enovis CORP report earnings next?
- February 4, 2027. Source: estimate_8k_pattern.
- Is Enovis CORP a public company?
- Yes. Enovis CORP files with the SEC under CIK 0001420800 and trades as ENOV.
- Who audits Enovis CORP?
- Ernst & Young LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Enovis CORP are outstanding?
- 57.7 million shares as of October 30, 2026, from its 10-Q filed November 5, 2026.
- What is Enovis CORP's public float?
- $1.9B as of July 4, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Enovis CORP report?
- 2 reportable segments for the period ending October 2, 2026, from its 10-Q filed November 5, 2026.
- When is Enovis CORP's annual shareholder meeting?
- April 6, 2026, per its proxy statement (DEF 14A) filed April 6, 2026.
- Have Enovis CORP insiders traded stock recently?
- Since August 13, 2025, officers and directors reported 0 open-market sales and 17 purchases worth about $1.4M on Forms 4 and 5. The most recent: Oliver Engert (Chief Administrative Officer) bought 2,660 shares on September 4, 2026.